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Abstract
Background data: Approximately 60% of osseous metastases are in the spine, and 10% of patients with spinal
metastases are expected to develop spinal cord compression. In our opinion, there is a need for a recent review of the
management of spinal metastases and the role of oncological spine surgeons due to recent advances in the diagnosis and
management of spinal metastases.
Purpose: This study aims to review the available data about the current concepts regarding decision making and
treatment options for spinal metastasis.
Study design: A narrative literature review was performed.
Patients and methods: The authors reviewed the English literature published over the past two decades for recent and
relevant data about decision making and treatment options in cases of spinal metastases. A PubMed search was conducted, and the most relevant articles according to the study aim and spine surgeon's practice were extracted.
Results: The classiﬁcation-based approaches described by Tokuhashi and colleagues and Tomita and colleagues are
well-established methods to estimate life expectancy in patients with spinal metastasis; however, they do not consider
newer radiotherapy technologies and chemotherapies to treat these metastases. Recent advances in molecular genetics
might explain why survival might be different in patients having the same tumor histopathology and metastases.
Survival is related to genes in tumors, and this is proven for melanoma, breast cancer, and non-small-cell lung cancer.
Neurologic, oncologic, mechanical, and systemic framework was recently developed and provided a comprehensive
assessment of metastatic spinal tumors, including four pillars: neurologic, oncologic, mechanical, and systemic assessment. In this framework, the role of oncological spine surgeons is limited to separation surgery or restoring spinal
stability, whereas the rest of the management depends mainly on radiotherapy. Targeted therapeutics are recent drugs
that have the potential to improve markedly the outcomes in cases of spinal metastases. Several targeted therapies have
been approved for metastatic renal cell carcinoma.
Conclusion: Prognosis in cases of spinal metastases seems to be more inﬂuenced by genetic subtyping. The role of
spinal oncological surgery is fading away. Surgery is limited to separation surgery and surgeries for restoration of spinal
stability. The future of spinal metastases management lies in the recent advances in techniques of radiotherapy and
targeted therapeutics (2021ESJ254).
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Introduction

S

pinal metastasis is known to occur in 30e50% of
patients with cancer [1]. Pain is the most

common symptom; however, 10% of cancer patients
present with a neural deﬁcit in the form of sensory
or motor deﬁcit, bowel and bladder incontinence,
and gait disturbances caused by spinal instability or
due to direct cord compression [2]. These patients
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are considered incurable [3,4]; thus, treatment is
aimed primarily at palliation rather than cure [5].
In our opinion, there is a need for a recent review
of the management of spinal metastases and the role
of oncological spine surgeons for several reasons.
First, patients with the metastatic spinal disease are
now expected to live longer owing to early diagnosis
of primary tumors with better imaging technologies,
like MR, ﬂuorodeoxyglucose-positron emission tomography, better treatment with advanced systemic
therapies like biologics, advances in radiation therapy, and better surgical techniques [6]. Second,
improvements in radiotherapy techniques, like
stereotactic body radiosurgery (SSRS), enable
accurate delivery of highly concentrated radiation to
the metastatic area, thus making the term ‘radioresistant tumors’ obsolete [6,7]. Third, minimally
invasive spine surgery (MISS) techniques are
introduced in managing spinal metastases [8].
Moreover, the guidelines and strategies dictating
the management of patients with spinal metastases
have been rendered less valid as they do not take
into consideration newer radiotherapy technologies
and chemotherapy regimens to treat these metastases [9e13].
This review article aims to provide an overview of
recent treatment protocols and the changing role of
a spine oncology surgeon in the management of
these conditions.
Decision-making systems
Decision making in cases of spinal metastases
should be a multidisciplinary approach that needs
cooperation between radiotherapy physicians,
spinal oncology surgeons, medical oncologists,
interventional radiologists, and pain management
specialists to improve their health-related quality of
life (HRQOL).
Although broad guidelines for managing patients
with spinal metastasis have been developed, they
are not universally accepted.
Tokuhashi score and Tomita surgical strategy
The classiﬁcation-based approaches described by
Tomita et al. [13] (Table 1) and Tokuhashi et al. [12]
(Table 2) are well-established methods to estimate
life expectancy in patients with spinal metastasis;
however, they fail to address important aspects of
patient care like a response to previous therapy and
do not take into consideration newer radiotherapy
technologies and chemotherapies to treat these
metastases as well. Published research works using
these two protocols for decision making in patients
with spinal metastases are contradictory, with a very

wide range of speciﬁcity, sensitivity, and accuracy
[1,10,14,15].
As an example of decision making using Tomita's
‘Surgical Strategy of Spinal Metastases,’ a case of a
57-year-old male presented in 2008 with severe low
back pain of 2 months and agonizing right sciatica of
1 month. On examination, neurological examination
was challenging to perform because of severe pain;
however, the sciatic nerve stretch test was positive at
30 . MRI demonstrated mass along the right side of
the L5 vertebral body (Fig. 1A-C). Computed
tomography (CT) (Fig. 1D) showed bone destruction
of the pedicle of L5 pedicle. Abdominal ultrasonography reported a mass measured 3  4 cm in the
right liver lobe. Tc bone scan and chest CT did not
demonstrate any other extraspinal metastases. Ultrasonography-guided biopsy from the liver mass
proved the diagnosis of hepatocellular carcinoma.
Using the ‘Surgical Strategy of Spinal Metastases,’
the patient's total score was 5. He was a candidate
for posterior decompression and stabilization,
which was subsequently used to treat metastases
(Fig. 1E). The patient had immediate postoperative
improvement in pain and received postoperative
conventional radiotherapy. The patient enjoyed
pain-free survival for 9 months until his death.
Primary tumor-based decision
Another school of thought regarding decision
making in patients with spinal metastases considers
primary tumor as the single most important factor.
Hence, several research works have tried to establish a clear policy for treating spinal metastases
originating from thyroid, renal, and breast cancers.
The senior author in the current manuscript coauthored four publications trying to establish a treatment policy for spinal metastases from thyroid
cancer [9e11,16]. This work was the base upon
which further trials were undertaken to develop an
algorithm to be used in managing spinal metastases
from thyroid and renal cancer [17].
Neurologic, oncologic, mechanical, and systemic
framework [18]
Neurologic, oncologic, mechanical, and systemic
framework was developed to overcome the shortcomings of the Tokuhashi score and Tomita Surgical
Strategy of Spinal Metastases. It provides a
comprehensive assessment of metastatic spinal
tumors. It has four pillars: neurologic, oncologic,
mechanical, and systemic assessment (Fig. 2). The
neurological
examination
assesses
myelopathyeradiculopathy-induced symptoms and assesses
radiologically Epidural Spinal Cord Compression
(ESCC) using the ESCC scale 7 (Fig. 3). The
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Table 1. Tomita surgical strategy of spinal metastases [13].

oncological assessment evaluates the predicted local
tumor control from radiation, chemotherapy, or
surgical intervention. The mechanical assessment
evaluated spinal instability, which may arise secondary to tumor spread and its sequelae using
the Spinal Instability Neoplastic Score (SINS) [20]
(Table 3). It also serves as an independent indication
for procedure-based interventions. Systemic assessment evaluates the various patient comorbidities and
predicts the ability of a patient to tolerate the procedure, the risk-to-beneﬁt ratio of treatment, and

expected survival. From this current framework, it is
evident that most of the cases are to be managed by
radiotherapy, either the conventional external mean
radiotherapy (CEBRT) or the SSRS. Surgery is indicated to restore the stability of an unstable spine or to
do decompression/separation surgery, preparing for
postoperative radiotherapy.
Molecular genetic-based decision
Recent advances in molecular genetics might
explain why survival might be different in patients

Table 2. Revised Tokuhashi score [12].
Parameters

Prognostic factors

Points

General condition (KPS)

Poor (KPS 10e40%)
Moderate (KPS 50e70%)
Good (KPS 80e100%)
>3
1e3
0
>3
1e3
0
Resectable
Unresectable
No metastasis
Lung, osteosarcoma, stomach, bladder,
esophagus, pancreas
Liver, gallbladder, unidentiﬁed
Others
Kidney, uterus
Rectum
Thyroid, prostate, breast, carcinoid
Complete (Frankel A, B)
Incomplete (Frankel C, D)
None (Frankel E)

0
1
2
0
1
2
0
1
2
0
1
2
0

Number of extraspinal bone metastatic foci

Number of metastases in a vertebral body

Metastasis to major organ

Primary site of cancer

Spinal cord palsy

Total points
0e8
9e11
12e15

1
2
3
4
4
0
1
2
Mean survival
<6 months
>6 months
>12 months
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Fig. 1. (A) MRI coronal STIR view of lumbosacral spine shows soft tissue mass at the right side of L5. (B) MRI sagittal STIR view showing the
metastases at L5. (C) MRI axial cut T2-weighted image at L5 showing the large soft tissue mass occupying the right side of L5 body and right pedicle
with epidural and extraspinal extension. (D) Preoperative CT at L5 level showing bone destruction at the body and right pedicle of L5. (E) Postoperative plain radiographs after posterior decompression and stabilization. CT, computed tomography.

having the same tumor histopathology and metastases. Survival seems to be related to genes in
tumors. This is proven for melanoma, breast cancer,
and non-small-cell lung cancer. If a melanoma
metastasis has a BRAF mutation in the genetic
phenotype of the primary tumor, survival is inﬂuenced by the response to immunotherapy rather
than by the number of spinal and visceral metastases
at presentation. The same is applied for epidermal
growth factor receptor status in non-small-cell lung
carcinoma and estrogen, progesterone, or HER2 receptor status in breast carcinoma. Thus, it is clear
that future decision making regarding spinal
metastases must take into consideration the genetic
subtype of the primary tumor [21].

Treatment options
Various treatment options for patients with spinal
metastasis include the following: (a) medical management, (b) radiation therapy, (c) surgery, and (d)
hybrid therapy.
Medical management
Pain management
Symptomatic management of pain is essential as
almost 90% of patients with metastatic disease suffer
from chronic debilitating pain [15]. This pain is
attributed to weakened bone leading to pathological
fractures and spinal instability. Pain may be radicular

Fig. 2. NOMS framework: low-grade ESCC is deﬁned as grade 0 or 1 on the Spine Oncology Study Group scoring system. High-grade ESCC is
deﬁned as grade 2 or 3 on the ESCC scale. Stabilization options include percutaneous cement augmentation, percutaneous pedicle screw instrumentation, and open instrumentation. For patients with signiﬁcant systemic comorbidities that affect the ability to tolerate open surgery, stabilization
may be limited to cement augmentation and/or percutaneous screw augmentation [18]. CEBRT, conventional external beam radiation; ESCC,
Epidural Spinal Cord Compression; NOMS, neurologic, oncologic, mechanical, and systemic; SSRS, spine stereotactic radiosurgery.
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due to nerve root involvement or myelopathic features due to cord compression. This pain is managed
by utilizing the pain ladder, starting with NSAIDs and
paracetamol for mild pain, opioids like tramadol for
moderate pain, and oxycodone and morphine for severe pain. Neuropathic pain is managed using tricyclic antidepressants, pregabalin, and gabapentin [22].

Fig. 3. Schematic representation of the six-point Epidural Spinal Cord
Compression (ESCC) grading scale. A grade of 0 indicates bone-only
disease; 1A, epidural impingement, without deformation of the thecal
sac; 1B, deformation of the thecal sac, without spinal cord abutment; 1C,
deformation of the thecal sac with spinal cord abutment, but without
cord compression; 2, spinal cord compression, but with CSF visible
around the cord; and 3, spinal cord compression, no CSF visible around
the cord [19].

Table 3. Spinal instability neoplastic score [20].
Factors
Location within the spine
Junctional (C0eC2, C7eT2, T11eL2, L5eS1)
Mobile spine (C3eC6, L2eL4)
Semirigid (T3eT10)
Rigid (S2eS5)
Pain relief with recumbence and pain with
movement or loading of the spine
Yes
No (occasional pain nonmechanical)
Pain-free lesion
Bone lesion quality
Lytic
Mixed lytic or blastic
Blastic
Radiographic spinal alignment
Subluxation or translation
De novo deformity
Normal alignment
Vertebral body collapse
>50% collapse
<50% collapse
No collapse with 50% body involvement
None of the above
Posterolateral involvement of spinal elements
Unilateral
Bilateral
None of the above

Points
3
2
1
0

3
1
0
2
1
0
4
2
0
3
2
1
0
3
1
0

Targeted therapeutics
The development of biologics and molecular
markers can enhance and augment the tumor responses to chemotherapy and result in a paradigm
shift in treatment. It has been noted that some
patients with lung adenocarcinoma have activated
endothelial growth factor receptor (EGFR) mutations. The presence of an EGFR mutation has been
shown to be a predictor of treatment efﬁcacy in
non-small-cell lung cancer. Several studies have
focused on developing EGFR inhibitors (i.e. erlotinib and geﬁtinib). The use of these tyrosine kinase
inhibitors has improved median overall survival in
non-small-cell lung cancer up to 24e36 months [23].
In cases of breast cancer bone metastases, the
identiﬁcation of molecular therapeutic targets has
the potential to markedly improve the outcomes in
these patients. The most notable molecular markers
that have yielded new therapies in treating breast
cancer are the estrogen receptor (ER) and HER2. In
patients with tumors positive for ER, the use of
tamoxifen, an ER antagonist, has led to markedly
improved survival [23].
Several targeted therapies have been approved for
metastatic renal cell carcinoma (RCC). These agents
include cytokines (interleukin-2), multitargeted RTK
inhibitors (TKI, i.e., sunitinib, pazopanib, axitinib,
and sorafenib, among others), mTOR inhibitor
(temsirolimus), and VEGF monoclonal antibody
(bevacizumab) in combination with interferonalpha. Ptashnikov et al. [24] retrospectively reviewed
100 patients of RCC with spinal metastases. Metastasectomy was performed in 39 cases, and 61
patients underwent decompression procedures with
stabilization. Only 26 patients had adjuvant-targeted
therapy (seven with metastasectomy and 19 with
palliative decompression). Their results showed a
statistically signiﬁcant better overall survival in
patients who received targeted therapy.
Radiation therapy
Radiotherapy has long been the treatment
modality of choice for metastatic spinal tumors. It
involves delivering a dose of radiation to a precisely
deﬁned area, which leads to tumor necrosis and
tumor shrinkage, thus allowing effective local tumor
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control. This shrinkage also helps with spinal
decompression and pain relief within 24 h of therapy [25]. Radiation therapy is usually administered
in two forms: CEBRT and SSRS.
Conventional external beam radiation
CEBRT has been the mainstay of spinal metastasis
management. It delivers multiple small additive
doses of radiation (usually 30 Gy in 10 fractions) to a
wide ﬁeld. Owing to the wide ﬁeld surrounding
normal soft tissues, the spinal cord is exposed to
large doses of radiation. Depending on the response
to therapy, tumors are classiﬁed as radiosensitive or
radioresistant. CEBRT-amenable radiosensitive
metastatic pathologies include hematological
malignancies, small-cell cancer, germ cell tumors,
and breast and prostate carcinomas. Radioresistant
tumors include solid tumors like tumors of kidney,
thyroid, hepatocellular, and colorectal origins [26].
Mizumoto et al. [27] have reported 2-year local
control rates of 86, 69, and 30% for breast, lung, and
gastrointestinal tumors, respectively, when treated
with CEBRT.
Spine stereotactic radiosurgery
SSRS has become the modality of choice in recent
years for achieving local control in cases of spinal
metastasis without signiﬁcant cord compression
[6,14]. This has been made possible by advances in
image guidance systems, which allows for high
biological equivalent hypofractionated dose to be
delivered with submillimeter accuracy to a contoured target volume with improved collateral
tissue sparing. SSRS can also be given as palliation
therapy, retreatment therapy, or both following
failed CEBRT [28].
Tumors conﬁned to bone (stage 0) and tumors with
minor epidural extension without abutment or
compression of the spinal cord (stages Ia and Ib), that
is, low-grade ESCC, have the requisite separation
from the spinal cord to be safely treated with SSRS. By
contrast, tumors displacing or compressing the spinal
cord (stages II and III, respectively) are classiﬁed as
high-grade ESCC and require resection of the
epidural component to separate the tumor from the
spinal cord before SSRS (separation surgery).
SSRS has multiple advantages over conventional
radiation therapy. SSRS allows the use of higher
biologically equivalent radiation doses (>10 Gy per
fraction), which damages tumor cell DNA leading to
tumor necrosis. It also causes additional damage to
the tumor vascular supply leading to hypoperfusion
of the tumor [29]. This allows successful application
of SSRS in traditionally radioresistant tumors like
RCC [30] and sarcoma [31].

Another advantage of SSRS is that it is delivered
in one to three fractions compared to 10 with 20
fractions of CEBRT, thus leading to better patient
compliance. Additionally, it can be used as deﬁnitive therapy in patients with spinal metastasis
without ESCC, thus replacing en bloc resection for
solitary metastasis used earlier [32]. Although
revolutionary, SSRS is associated with its own set of
complications, primarily being dose-dependent
toxicity. Patients undergoing SSRS have an
increased incidence of vertebral compression fractures; however, this is usually associated with highdose therapy [33].
Another dose-dependent complication is of the
spinal cord in the form of radiation-induced
myelopathy in ESCC management and epidural
disease progression [31]. Thus, a balance needs to be
achieved, which allows successful patient management: on the one hand, it prevents low/suboptimal
dose-related treatment failure, whereas on the other
hand it prevents high-dose-dependent toxicities.
We consider that radioresistant tumors with highgrade ESCC are better managed with surgical
decompression [31].
Intraoperative radiation therapy
The use of SSRS has led to the paradigm shift in
treating patients with spinal metastasis; however, it
has less role in patients with circumferential tumors
around the dura and those with a previous history of
radiation therapy because of the increased complication of spinal cord toxicity. This has led to the use
of intraoperative radiation therapy, which allows the
delivery of a single dose of therapeutic radiation to
the dural margin using a short-ranged source. This
allows delivery of a high dose of 25 Gy fraction to
the dura while sparing the spinal cord [34].
Surgical intervention
The surgical approach is dependent on the level
of lesions, the extent of bone involvement, and
surgeon preference. Traditional surgical interventions include posterior decompression, stabilization, and debunking surgery (piecemeal
excision or even en-bloc spondylectomy)
[9e11,13,35]. However, surgical interventions are
associated with varying degrees of complications
and associated surgical morbidities. These ranged
from 21 to 26% and correlated with the extent of
surgical procedure and use of preoperative radiation therapy [36].
With radiosensitive metastasis being managed by
CEBRT and radioresistant metastasis being managed
with SSRS, the need for cytoreductive surgery has
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declined. Indications for surgery currently might
include evidence of neurological function deterioration especially if caused by compression by a bone
fragment, spinal instability (assessed using SINS)
causing pain and neurological deﬁcit or tumor progression despite RT, neurological deﬁcit persisting
after RT, unproven cancer histology, signiﬁcant
metastatic spinal cord compression (using ESCC
scale), and a life expectancy of at least 3 months.
Surgery allows immediate decompression of the
neural elements while providing spinal stabilization
and histological diagnosis [37].
Spine Oncology Study Group deﬁned spinal
instability as a ‘loss of spinal integrity as a result of a
neoplastic process that is associated with movement-related pain, symptomatic or progressive
deformity, and/or neural compromise under physiological loads’ [20].
SINS (Table 3) is currently the most accepted
method for evaluating mechanical instability in spinal tumors. High SINS (13e18) reliably predict the
need for surgical stabilization, whereas low SINS
(0e6) are considered stable, and the intermediate
SINS (7e12) tumors need further reﬁnement, but
essentially the need for treatment is based on the
discretion and experience of the spine surgeon [19].
MISS. For the surgical procedures to be of actual
beneﬁt, the associated surgical morbidity should be
minimal, thus allowing for early recovery and
improved HRQOL. This has led to the adoption of
MISS principles in the treatment of spinal metastasis. MISS allows early postsurgical irradiation,
with some patients being treated within 3 days of
surgery using the stereotactic technique [38]. Thus,
MISS provides signiﬁcant beneﬁts compared with
traditional surgery, where an already terminal patient has to wait for a prolonged period to allow for
adequate wound healing before starting radiation
therapy. Recent study comparing open surgery
with MISS for treatment of symptomatic vertebral
metastasis has also concluded that MISS has
shorter operative times, shorter recovery times,
better pain improvement, and comparable neurological function while having lower complication
rates [39].
Combined surgery and radiotherapy
Combined surgery and radiation therapy has
become the standard of care in patients with good
performance status, oligometastatic disease, and
vertebral metastases causing instability or ESCC
with neurological deﬁcits. A combined surgery and
radiation therapy offers a signiﬁcant advantage: the
radiation therapy provides local tumor control,
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whereas the surgery helps with neural decompression and spinal stabilization. In a randomized
controlled study of surgical decompression with
conventional radiotherapy (30 Gy in 10 fractions)
compared with radiotherapy alone for metastatic
ESCC secondary to solid malignancies, Patchell et al.
[40] demonstrated the superiority of a combined
surgical and radiotherapeutic approach for the
maintenance and recovery of ambulation, duration
of ambulation, functional ability, maintenance of
continence, and survival [40]. Recent multicenter
prospective studies have also shown a signiﬁcant
improvement in HRQOL of patients undergoing a
combination of surgery and radiotherapy.
Consensus guidelines for the use of postoperative
SRSS based on an international survey have
concluded that postoperative SRSS may be indicated for (a) radioresistant primary histology, (b)
disease that is conﬁned to one to two vertebral
levels, and (c) prior overlapping or adjacent
conventional RT.
Moreover, the consensus opinion was that postoperative SSRS is contraindicated in cases of residual
postoperative severe spinal cord compression (Bilsky
grade 3) and complete spinal cord injury (ASIA grade
A) and when more than three contiguous vertebral
levels are involved. For treatment planning, the preoperative MRI and postoperative T1-weighted MRI
(with and without gadolinium) should be coregistered and delineation of the cord should be performed using coregistered T1-weighted and/or
T2-weighted MRI or a CT myelogram in cases of
signiﬁcant hardware artifact [41].
A meta-analysis by Klimo and Schmidt [42]
reported that surgery should be the primary treatment in patients with spinal epidural disease, with
radiotherapy used as an adjunct.
Multiple studies have reported that postoperative
adjuvant SRSS following separation surgery is safe
and effective in achieving local tumor control
[42,43]. However, complications include hardware
failure, seen in ~2.8% of the cases [44].
Study limitations
This review is not a systematic review. We intentionally neglected to discuss classiﬁcations of spinal
tumors as they were previously discussed in several
research works. Moreover, the effect of these classiﬁcations in decision making is fading. For sure,
many suggested scores and algorithms cannot be
included in the current review, so we reported the
most frequently used. We did not discuss en bloc
excision of spinal metastases as it was previously
discussed and, again, its indications are currently
very limited.
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Recommendation
Several unresolved topics related to managing
spinal metastases are still waiting for prospective,
well-designed studies. It seems that well-planned
studies should be directed toward studying the
survival of patients having spinal metastases from
every genetic subtype of various tumors separately.
Although it seems difﬁcult and needs multicenter
collaboration, such studies will give clues to a lot of
questions related to the expected survival of the
patients and consequently facilitate decision
making. Furthermore, the inclusion of targeted
therapeutics in the algorithm for treating spinal
metastases needs well-planned studies to detect the
best line of treatment for every patient.
Conclusion
Prognosis in cases of spinal metastases seems to
be more inﬂuenced by genetic subtyping. The role
of spinal oncological surgery is fading away, and
surgery is limited to separation surgery and surgeries to restore spinal stability. The future of
spinal metastases management lies in the recent
advances in radiotherapy techniques and targeted
therapeutics.
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Abbreviation list
MRI
Magnetic resonance imaging
FDG-PET Fluorodeoxyglucose-positron emission tomography
SSRS
Stereotactic body radiosurgery
MIS
Minimally invasive spine surgery
HRQOL Health-related quality of life
ESCC
Epidural Spinal Cord Compression
SINS
Spinal Instability Neoplastic Score
CEBRT Conventional external mean radiotherapy
NSAIDs Nonsteroidal anti-inﬂammatory drugs
NSCLC Non-small-cell lung cancer
HR
Estrogen receptor
RCC
Renal cell carcinoma
SOSG
Spine Oncology Study Group
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ﺍﻟﻤﻠﺨﺺ ﺍﻟﻌﺮﺑﻲ
ﺍﻻﺗﺠﺎﻫﺎﺕ ﺍﻟﺤﺪﻳﺜﺔ ﻓﻲ ﺇﺩﺍﺭﺓ ﻭﺭﻡ ﺛﺎﻧﻮﻯ ﺧﺒﻴﺚ ﻓﻲ ﺍﻟﻌﻤﻮﺩ ﺍﻟﻔﻘﺮﻱ

ﻣﺮﺍﺟﻌﺔ ﺳﺮﺩ ﻟﻸﺩﺑﻴﺎﺕ

ﺍﻟﺒﻴﺎﻧﺎﺕ ﺍﻟﺨﻠﻔﻴﻪ ﺍﻟﻌﻤﻮﺩ ﺍﻟﻔﻘﺮﻱ ﻫﻮ ﺍﻟﻤﻮﻗﻊ ﺍﻷﻛﺜﺮ ﺷﻴﻮ ًﻋﺎ ﻟﻠﺜﺎﻧﻮﻳﺎﺕ ﺍﻟﺴﺮﻃﺎﻧﻴﻪ ﻭﺣﻮﺍﻟﻲ  ٪60ﻣﻦ ﺍﻟﺜﺎﻧﻮﻳﺎﺕ ﺍﻟﻌﻈﻤﻴﺔ ﺗﻜﻮﻥ ﻓﻲ ﺍﻟﻌﻤﻮﺩ ﺍﻟﻔﻘﺮﻱ ﻭﻣﻦ ﺍﻟﻤﺘﻮﻗﻊ ﺃﻥ ﻳﻌﺎﻧﻲ  ٪10ﻣﻦ
ﻣﺮﺿﻰ ﺍﻟﺜﺎﻧﻮﻳﺎﺕ ﺍﻟﺴﺮﻃﺎﻧﻴﻪ ﺍﻟﻔﻘﺎﺭﻳﻪ ﻣﻦ ﺣﺪﻭﺙ ﺿﻐﻂ ﻋﻠﻲ ﺍﻟﻨﺨﺎﻉ ﺍﻟﺸﻮﻛﻲ .ﻓﻲ ﺭﺃﻳﻨﺎ  ،ﻫﻨﺎﻙ ﺣﺎﺟﺔ ﻟﻤﺮﺍﺟﻌﺔ ﺣﺪﻳﺜﺔ ﻟﻌﻼﺝ ﺍﻟﺜﺎﻧﻮﻳﺎﺕ ﺍﻟﺴﺮﻃﺎﻧﻴﻪ ﺍﻟﻔﻘﺮﻳﻪ ﻭﺩﻭﺭ ﺟﺮﺍﺡ ﺍﻟﻌﻤﻮﺩ ﺍﻟﻔﻘﺮﻱ
.ﺑﺴﺒﺐ ﺍﻟﺘﻄﻮﺭﺍﺕ ﺍﻟﺤﺪﻳﺜﺔ ﻓﻲ ﻣﺠﺎﻻﺕ ﺗﺸﺨﻴﺺ ﻭﻋﻼﺝ ﺗﻠﻚ ﺍﻟﺤﺎﻻﺕ

ﺍﻟﻐﺮﺽ

ﻣﺮﺍﺟﻌﺔ ﺍﻟﺒﻴﺎﻧﺎﺕ ﺍﻟﻤﺘﻮﻓﺮﺓ ﺣﻮﻝ ﺍﻟﻄﺮﻕ ﺍﻟﺤﺪﻳﺜﻪ ﻓﻲ ﻋﻼﺝ ﺍﻟﺜﺎﻧﻮﻳﺎﺕ ﺍﻟﻔﻘﺎﺭﻳﻪ ﺍﻟﺨﺒﻴﺜﻪ

.ﺗﺼﻤﻴﻢ ﺍﻟﺪﺭﺍﺳﺔ
ﺍﻟﻤﺮﺿﻰ ﻭﺍﻟﻄﺮﻕ

ﺍﻟﺨﺒﻴﺜﻪ ﺑﺎﻟﻔﻘﺮﺍﺕ

ﻣﺮﺍﺟﻌﺔ ﺍﻷﺩﺏ ﺍﻟﺴﺮﺩﻱ
ﺭﺍﺟﻊ ﺍﻟﻤﺆﻟﻒ ﺍﻷﺑﺤﺎﺙ ﺍﻟﻤﻨﺸﻮﺭﻩ ﺧﻼﻝ ﺍﻟﻌﻘﺪﻳﻦ ﺍﻟﻤﺎﺿﻴﻴﻦ ﻟﻠﺤﺼﻮﻝ ﻋﻠﻰ ﺑﻴﺎﻧﺎﺕ ﺣﺪﻳﺜﺔ ﻭﺫﺍﺕ ﺻﻠﺔ ﺣﻮﻝ ﺍﺗﺨﺎﺫ ﺍﻟﻘﺮﺍﺭ ﻭﺧﻴﺎﺭﺍﺕ ﺍﻟﻌﻼﺝ ﻓﻲ ﺣﺎﻻﺕ ﺍﻟﺜﺎﻧﻮﻳﺎﺕ

ﺍﻟﻨﺘﺎﺋﺞ ﺍﻟﻨﻬﺞ ﺍﻟﻘﺎﺋﻢ ﻋﻠﻰ ﺍﻟﺘﺼﻨﻴﻒ ﺍﻟﺬﻱ ﻭﺻﻔﻪ ﻛﻞ ﻣﻦ ﺗﻮﻣﻴﺘﺎ ﻭ ﺗﻮﻛﻮﻫﺎﺷﻰ ﻫﻲ ﻃﺮﻕ ﺭﺍﺳﺨﺔ ﻟﺘﻘﺪﻳﺮ ﻣﺘﻮﺳﻂ ﺍﻟﺤﻴﺎﺓ ﺍﻟﻤﺘﻮﻗﻊ ﻓﻲ ﺍﻟﻤﺮﺿﻰ ﺍﻟﺬﻳﻦ ﻳﻌﺎﻧﻮﻥ ﻣﻦ ﻭﺭﻡ ﺛﺎﻧﻮﻱ ﺧﺒﻴﺚ ﻓﻲ
ﺍﻟﻌﻤﻮﺩ ﺍﻟﻔﻘﺮﻱ  ،ﻟﻜﻨﻬﺎ ﻻ ﺗﺄﺧﺬ ﻓﻲ ﺍﻻﻋﺘﺒﺎﺭ ﺃﺣﺪﺙ ﺗﻘﻨﻴﺎﺕ ﺍﻟﻌﻼﺝ ﺍﻹﺷﻌﺎﻋﻲ ﻭﺍﻟﻌﻼﺝ ﺍﻟﻜﻴﻤﻴﺎﺋﻲ ﻟﻌﻼﺝ ﻫﺬﻩ ﺍﻟﺜﺎﻧﻮﻳﺎﺕ .ﻗﺪ ﺗﻔﺴﺮ ﺍﻟﺘﻄﻮﺭﺍﺕ ﺍﻟﺤﺪﻳﺜﺔ ﻓﻲ ﻋﻠﻢ ﺍﻟﻮﺭﺍﺛﺔ ﺍﻟﺠﺰﻳﺌﻲ ﺳﺒﺐ ﺍﺧﺘﻼﻑ
ﺍﻟﺒﻘﺎﺀ ﻋﻠﻰ ﻗﻴﺪ ﺍﻟﺤﻴﺎﺓ ﻓﻲ ﺍﻟﻤﺮﺿﻰ ﺍﻟﺬﻳﻦ ﻳﻌﺎﻧﻮﻥ ﻣﻦ ﻧﻔﺲ ﺍﻟﺘﺸﺮﻳﺢ ﺍﻟﻤﺮﺿﻲ ﻟﻠﻮﺭﻡ ﻭﻧﻔﺲ ﺍﻟﺜﺎﻧﻮﻳﺎﺕ .ﺍﻟﺒﻘﺎﺀ ﻋﻠﻰ ﻗﻴﺪ ﺍﻟﺤﻴﺎﺓ ﻣﺮﺗﺒﻂ ﺑﺎﻟﺠﻴﻨﺎﺕ ﻓﻲ ﺍﻷﻭﺭﺍﻡ .ﺛﺒﺖ ﻫﺬﺍ ﻓﻲ ﺳﺮﻃﺎﻥ ﺍﻟﺠﻠﺪ
ﻣﺆﺧ ًﺮﺍ ﻭﻳﻮﻓﺮ ﺗﻘﻴﻴ ًﻤﺎ ﺷﺎﻣ ًﻼ ﻟﻼﻭﺭﺍﻡ ﺍﻟﺜﺎﻧﻮﻳﻪ ﺍﻟﺨﺒﻴﺜﻪ ﺑﺎﻟﻔﻘﺮﺍﺕ .ﻳﺤﺘﻮﻱ ﻫﺬﺍ ﺍﻟﺘﻘﻴﻴﻢ ﻋﻠﻰ  4ﺃﻋﻤﺪﺓ  NOMSﻭﺳﺮﻃﺎﻥ ﺍﻟﺜﺪﻱ ﻭﺳﺮﻃﺎﻥ ﺍﻟﺮﺋﺔ ﺫﻭ ﺍﻟﺨﻼﻳﺎ ﻏﻴﺮ ﺍﻟﺼﻐﻴﺮﺓ .ﺗﻢ ﺗﻄﻮﻳﺮ ﺇﻃﺎﺭ
ﺗﻘﻴﻴﻤﺎﺕ ﻋﺼﺒﻴﺔ  ،ﻭﺃﻭﺭﺍﻡ  ،ﻭﻣﻴﻜﺎﻧﻴﻜﻴﻪ  ،ﻭﺍﻟﺤﺎﻟﻪ ﺍﻟﻌﺎﻣﻪ ﻟﻠﻤﺮﻳﺾ .ﻓﻲ ﻫﺬﺍ ﺍﻹﻃﺎﺭ ﻓﺈﻥ ﺩﻭﺭ ﺟﺮﺍﺣﻲ ﺍﻟﻌﻤﻮﺩ ﺍﻟﻔﻘﺮﻱ ﻟﻸﻭﺭﺍﻡ ﻫﻮ ﻓﻘﻂ ﺇﺟﺮﺍﺀ ﺟﺮﺍﺣﺔ ﺍﻟﻔﺼﻞ ﺍﻟﻮﺭﻡ ﻋﻦ ﺍﻟﻨﺨﺎﻉ ﺍﻟﺸﻮﻛﻲ ﺃﻭ
ﺍﺳﺘﻌﺎﺩﺓ ﺛﺒﺎﺕ ﺍﻟﻌﻤﻮﺩ ﺍﻟﻔﻘﺮﻱ ﺑﻴﻨﻤﺎ ﺗﻌﺘﻤﺪ ﺑﻘﻴﺔ ﻭﺳﺎﺋﻞ ﺍﻟﻌﻼﺝ ﺑﺸﻜﻞ ﺃﺳﺎﺳﻲ ﻋﻠﻰ ﺍﻟﻌﻼﺝ ﺍﻹﺷﻌﺎﻋﻲ .ﺍﻟﻌﻼﺟﺎﺕ ﺍﻟﻜﻴﻤﺎﻭﻳﻪ ﺍﻟﻤﺴﺘﻬﺪﻓﺔ ﻫﻲ ﺍﻷﺩﻭﻳﺔ ﺍﻟﺤﺪﻳﺜﺔ ﺍﻟﺘﻲ ﻟﺪﻳﻬﺎ ﺍﻟﻘﺪﺭﺓ ﻋﻠﻰ ﺗﺤﺴﻴﻦ
ﺍﻟﻨﺘﺎﺋﺞ ﺑﺸﻜﻞ ﻣﻠﺤﻮﻅ ﻓﻲ ﺣﺎﻻﺕ ﺍﻟﺜﺎﻧﻮﻳﺎﺕ ﺍﻟﺨﺒﻴﺜﻪ ﺑﺎﻟﻔﻘﺮﺍﺕ ﻭ ﻗﺪ ﺗﻤﺖ ﺍﺟﺎﺯﺓ ﺍﻟﻌﺪﻳﺪ ﻣﻦ ﺍﻟﻌﻼﺟﺎﺕ ﺍﻟﻤﺴﺘﻬﺪﻓﺔ ﻟﺴﺮﻃﺎﻥ ﺍﻟﻜﻠﻲ
ﺍﻟﺨﻼﺻﻪ ﻳﺒﺪﻭ ﺃﻥ ﻧﺘﻴﺠﺔ ﻋﻼﺝ ﺣﺎﻻﺕ ﺍﻟﺜﺎﻧﻮﻳﺎﺕ ﺍﻟﺨﺒﻴﺜﻪ ﺑﺎﻟﻔﻘﺮﺍﺕ ﻳﺘﺄﺛﺮ ﺃﻛﺜﺮ ﺑﺎﻟﺘﺼﻨﻴﻒ ﺍﻟﺠﻴﻨﻲ ﻟﻠﻮﺭﻡ ﺍﻻﻡ .ﺩﻭﺭ ﺟﺮﺍﺡ .ﺍﻭﺭﺍﻡ ﺍﻟﻌﻤﻮﺩ ﺍﻟﻔﻘﺮﻱ ﻳﺘﻀﺎﺋﻞ ﺗﺪﺭﻳﺠﻴﺎ ﻭ ﻳﻨﺤﺼﺮ ﺩﻭﺭﻩ ﻓﻲ
ﺍﺟﺮﺍﺀ ﺟﺮﺍﺣﺔ ﻓﺼﻞ ﺍﻟﻮﺭﻡ ﻋﻦ ﺍﻟﻨﺨﺎﻉ ﺍﻟﺸﻮﻛﻲ ﻭﺍﺳﺘﻌﺎﺩﺓ ﺛﺒﺎﺕ .ﺍﻟﻌﻤﻮﺩ ﺍﻟﻔﻘﺮﻱ .ﺍﻟﻤﺴﺘﻘﺒﻞ ﻓﻲ ﻋﻼﺝ ﺍﻟﺜﺎﻧﻮﻳﺎﺕ ﺍﻟﺨﺒﻴﺜﻪ ﺑﺎﻟﻔﻘﺮﺍﺕ ﻫﻮ ﺍﻟﺘﻘﻨﻴﺎﺕ ﺍﻟﺤﺪﻳﺜﺔ ﻟﻠﻌﻼﺝ ﺍﻹﺷﻌﺎﻋﻲ ﻭﺍﻟﻌﻼﺟﺎﺕ
.ﺍﻟﻜﻴﻤﺎﻭﻳﻪ ﺍﻟﻤﺴﺘﻬﺪﻓﺔ

